Sean Sachdev, MD

Radiation Oncologist, Associate Professor at @NorthwesternMed @LurieCancer. #radonc #btsm #pcsm tweets = own opinion

[NEJM @NEJM]

Adaptive radiotherapy involves modifying treatment plans to account for changes in anatomical geometry that are not adequately mitigated with changes in alignment. Online adaptive radiotherapy capitalizes on advances in image guidance, real-time tumor tracking, and the enhanced speed of multiple steps in radiotherapy planning and delivery workflows (seen in image).

Learn more in the Review Article “Effects of Radiotherapy in Normal Tissue” by @DeborahCitrin, MD, and Robert D. Timmerman, MD (@BobTimmermanMD), from the National Cancer Institute and @UTSWMedCenter: https://t.co/glyNSgSazP

[Sean Sachdev, MD @SeanSachdevMD]

Excellent deep dive by @DrKarineTawagi on the modern systemic landscape for MIBC. A comprehensive look at current standards and the future considerations shaping the field. 🧬 #UroOnc #BladderCancer @ChiUroSociety

[Karine Tawagi MD @DrKarineTawagi]

PRO bladder preservation @SeanSachdevMD vs PRO cystectomy debate @ChiUroSociety urothelial meeting

#GU015 trial ongoing looking at SBRT vs hypofractionated RT in TMT

Framework for pt selection for TMT by @shilpaonc et al @EuropeanUrology

💡proposed framework for the future

[Chad Tang, MD @ChadTangMD]

Extremely excited to share our latest article published @TheLancetOncol a few hours ago: https://t.co/du9hQOzHv7.

The WOLVERINE individual patient meta-analysis was an international collaboration and part of X-MET collaboration. Goal was to evaluate MDT in oligomet prostate ca.

[Dr. Jason Efstathiou @drjefstathiou]

Great to reconnect with so many motivated clinical trialists, colleagues, and the #GU family at the @NRGOnc Winter Meeting #NRG2026!

2025 was a big year for NRG GU with landmark trials presented at ASTRO in plenary and clinical trials sessions (GU005, RTOG 0924, GU006) and two major bladder trials that were launched:
🔹 NRG GU014 PARRC 💉 — RT+IO vs chemoRT in NMIBC
🔹 NRG GU015 ARCHER 🏹 — 20 vs 5 (adaptive) fractions chemoRT in MIBC

Lots more to come in 2026! Grateful to the PIs and study teams—and especially to the patients and families who make NRG trials possible.

@snseyedinMD @jmmrad @DrHowardSandler @NehaVapiwala @DrPaulNguyen @RonaldChenMD @MaryFengMD @ChadTangMD @KHoffmanMD @BrianBaumannMD @CaPsurvivorship @EdwinPosadasMD @MiyamotoDavid @abhiAsolanki @bridget_koontz @MoningiShalini @HimanshuNagarMD @UroCancer @DrSpratticus @Katie_Spina @TylerSbrt @sophia_kamran @tranpt21 @aleberlin2 @a_dalpra @ndesai2005 @SeanSachdevMD @MassGenBrigham @NRGonc

#NRGOncology #RadiationOncology #GUCancer #CancerResearch #OncologyCommunity #BladderCancer #ClinicalTrials #TeamScience

[Dr. Jason Efstathiou @drjefstathiou]

🏹 Randomized Phase III Trial: Adaptive Radiation and Chemotherapy For Muscle Invasive Bladder Cancer (ARCHER)

Congratulations to the NRG GU015 ARCHER study team led by @UroCancer and @HimanshuNagarMD for the recent activation and launch of this cutting-edge and patient-centric bladder-sparing phase III trial that investigates many novel interventions including ultrahypofractionation/SBRT, adaptive radiation, ctDNA as a biomarker, and allows for any neoadjuvant systemic therapy. Please support this important study!

#CancerResearch #RadiationOncology #Urology #MedicalOncology #MIBC #ClinicalTrial #ClinicalResearch

@DrPaulNguyen @Shilpaonc @danielxingao @SeanSachdevMD @KellyStratton @AdityaBagrodia @ndesai2005 @Jonathan_Leeman @KashaniRojano @KateMRGuidance @DrMBWesterman @abhiAsolanki @MiyamotoDavid @Katie_Spina @jamesmgtsui @NRGOnc @MGHCancerCenter @urotoday @BladderCancerUS @MassGenBrigham

[Dr. Jason Efstathiou @drjefstathiou]

On Monday, I will present the key PARTIQoL trial results at the 2024 @ASTRO_org Annual Meeting! 🎉 I'll cover the potential benefits of #ProtonTherapy, & innovative patient recruitment strategies. Let me know if you are attending #ASTRO2024 too!

[Sean Sachdev, MD @SeanSachdevMD]

Honored to host Dr. Albert Koong @ACKoongMDPhD, Chair of RadOnc at MD Andreson, as the distinguished speaker for our annual resident retreat. He started us off with a wonderful talk this morning.

[Sean Sachdev, MD @SeanSachdevMD]

@DrJuneJD Thank you!

[Sean Sachdev, MD @SeanSachdevMD]

Really honored and humbled to receive the 2024 Christopher Getch Clinical Excellence Award from @NeurosurgeryNM

Proud to participate in the care of brain tumor patients and contribute to the education of neurosurgery residents #btsm

[Sean Sachdev, MD @SeanSachdevMD]

Happy to see Melanie of @LurieCancer represent at #ASCO24 in full #purpleglory

[Sean Sachdev, MD @SeanSachdevMD]

@CraigHorbinski presenting more of his excellent work suggesting that brainstem infiltration by resistant, aggressive glioma cells may be responsible for disease recalcitrance and progression. #ASCO24 #btsm

[Sean Sachdev, MD @SeanSachdevMD]

@_ShankarSiva - #radonc who has played a key role in validating the role of SABR/SBRT for RCC, presenting an excellent overview of novel imaging strategies ahead #ASCO24

[Sean Sachdev, MD @SeanSachdevMD]

@d_golden @chr_huang @roecsg @KimCorbinMD This is factual

[PDBrown @PDBrownOnc]

ASTRO PLENARY Session LBA 04 Randomized trial PCI vs HA-PCI:

HA-PCI is a standard of care for Small cell lung cancer

[Sean Sachdev, MD @SeanSachdevMD]

ASTRO Plenary: 5-fraction SBRT/SABR non-inferior at 5y compared to more protracted treatment (PACE-B). Detailed toxicity reporting, great work by @nickva1 @alison_tree @ICR_CTSU #ASTRO23

[ACROresident @ACROresident]

👩‍🏫📚🎉 Congratulations to our Dr. Luther Brady Educational Grant winners! 🎉📚👩‍🏫

Amulaya Yalamanchili, Northwestern University, @amulyayala
Michelle Tibbs @UCSDRadMed @shelley_tibbs
Ramez Kouzy @MDAndersonNews @RKouzyMD
Michael Rooney @MDAndersonNews @MichaelRooney67

[Cliff Robinson @SBRT_CR]

Had a blast giving a talk and hanging out with @NorthwesternMed #radonc residents and students as visiting professor! The future is bright for our field! 🌟☢️ @SeanSachdevMD @JamesRandallMD1
@SalahDajaniMD @AmulyaYala @George_E_Naoum @Zheng_Shuhua @WashURadOnc

[Sean Sachdev, MD @SeanSachdevMD]

@ChadTangMD @ndesai2005 @VedangMurthy @piet_ost @agomeziturriaga @DrAndrewLoblaw @alison_tree @AmarUKishan @DrSpratticus @ACKoongMDPhD @PBlanchardMD Excellent work @ChadTangMD, looking forward to going through the details!!

[Yüksel Ürün @DrYukselUrun]

TRIP did not demonstrate the superiority of 30 months vs. 6 months of ADT when combined with brachytherapy and EBRT.! Atsunori Yorozu, MD, PhD
#GU23 @ASCO @OncoAlert @urotoday @PCFnews @OncBrothers @APCCC_Lugano @HemOncFellows
#prostatecancer @Uromigos #MedTwitter